0
2015
Castration-resistant Prostate Cancer (crpc)/hrpca Therapeutics Market

Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market

by Therapy Type (Chemotherapy, Hormonal Therapy, Immunotherapy, Radiotherapy) and Drug Delivery Method (Oral Therapy, Injectable Therapy) - Global Opportunity Analysis and Industry Forecast, 2014 - 2020

Report Code: A00568
Pages: 122
Jul 2015 | 14762 Views
Author(s) : Hardik S
Tables: 48
Charts: 46
  • Formats*:

  • Single User License, Five User
    License & Enterprise User License

  • Data Pack Excel License

  • It comes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Castration-resistant Prostate Cancer (crpc)/hrpca Therapeutics Market

Request Now !

Castration-Resistant Prostate Cancer Therapeutics Market Overview:

CRPC Therapeutics Market is expected to garner $9.5 billion by 2020, registering a CAGR of 9.1% during the forecast period 2015-2020.

Castration-Resistant Prostate Cancer (CRPC) or Hormone Refractory Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after administering androgen deprivation therapy (ADT), is gaining prominence in the prostate cancer market. The global CRPC market is poised to expand at a significant pace, owing to high unmet clinical need, limited survival benefits, growing prevalence rates and fast emerging treatment modifications. The market growth would pivot around the novel breakthrough treatments responsible for reaping survival benefits. The survival benefit would be instrumental in governing the peak sales and market penetration of novel approved drugs.

Promising drug pipeline, evolving treatment patterns, emerging untapped non-metastatic CRPC space and augmented patient awareness are the factors that are expected to boost the market growth. Further, untapped CRPC market in the Asia-Pacific and LAMEA region would also accelerate the overall market growth during the forecast period. Untapped non-metastatic CRPC settings would further bolster the market growth. On the other hand, factors such as premium pricing of CRPC drugs, uncertain reimbursement policies and lack of differentiation in mechanism of action among the approved and novel agents are likely to curtail the market growth.

The market would gain traction in the developing regions of Asia-Pacific and third-world countries such as Africa and Latin America. The large undiagnosed patient population, rapid urbanization, rising disposable income, improved government funding towards cancer and growing awareness about prostate cancer would be some of the prime reasons responsible for the unparalleled market growth in these regions. However, oncologists/urologists reluctance towards adoption of these premium treatments in countries like India and China would continue to remain a key challenge for the leading innovators.

To provide a detailed market assessment, the report segments the CRPC market on the basis of therapy type, drug delivery method and geography. Based on therapy type, the market is segmented across various segments such as Chemotherapy, Hormonal Therapy, Immunotherapy and Radiotherapy. Hormonal therapy segment spearheads the therapy types market, governing around 4/5th of the global market value in 2014 and would continue to maintain its market position during the forecast period (2015-2020). Radiation therapy segment is projected as the fastest growing segment throughout the forecast period. Based on drug delivery method, the market is segmented into oral and injectable therapy segments. Oral therapy segment dominates the global CRPC market; however, injectable segment is expected to grow at a faster rate. The report covers a geographic breakdown and a detailed analysis of each of the aforesaid segments across North America, Europe, Asia Pacific and LAMEA regions. North America region governs a dominant share in the global CRPC market; however, Asia-Pacific and LAMEA region are expected to register the highest CAGR during the forecast period.

The market registered substantial growth in the recent years, owing to the various strategies adopted by leading market players. One of the key strategies adopted is collaboration agreement. Astellas Pharma Inc. for instance in 2009, entered into an agreement with Medivation, Inc. to co-develop and co-commercialize MDV3100 (now Xtandi) for the treatment of CRPC. A comprehensive competitive analysis and profiles of major market players such as Astellas Inc., Johnson & Johnson, Sanofi S.A, Dendreon Corporation, Bayer AG, and others have been provided in the report.

Castration-Resistant-Prostate-Cancer-Sidebar.jpg

KEY MARKET BENEFITS:

  • This report provides an extensive analysis of the current and emerging market trends and dynamics in the global CRPC (metastatic and non-metastatic) market

  • The CRPC market scenario is comprehensively analysed in accordance to the key regions

  • In-depth analysis of CRPC (chemotherapy and post-chemo) settings is implemented in the report

  • The market estimations are made in the report by conducting high-end analysis of the key market segments for the period of 2014-2020

  • Extensive research is done for the market by therapy type which instils a clear understanding regarding the currently used therapy drugs and evolving role of immunotherapies and radiopharmaceuticals

  • A detailed SWOT analysis enables to study the internal environment of the leading companies for strategy formulation

  • Owing to an emerging pipeline in the market, pipeline analysis studies have also been taken into account to better understand the market potential and opportunities

  • Competitive intelligence highlights the business practises followed by leading market players across geographies

Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Report Highlights

Aspects Details
BY THERAPY TYPE
  • HormonalTherapy
  • Chemotherapy
  • Immunotherapy
  • Radiotherapy
BY DRUG DELIVERY METHOD
  • Oral Route
  • Injectable route
BY GEOGRAPHY
  • NorthAmerica
  • Europe
  • Asia-Pacific
  • LAMEA
Key Market Players Johnson & Johnson, Dendreon Corporation, Sanofi, Bayer, Astellas Pharma Inc.
 

Loading Table Of Content...


 
 
PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : + 44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Request Free Sample

Purchase Full Report of
Castration-resistant Prostate Cancer (crpc)/hrpca Therapeutics Market

Start reading instantly.
This Report and over 19,665+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,217
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
    (Jul 2016 - Jul 2017)
  • Data Pack
  • $3,574
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Jul 2016 - Jul 2017)
  • Single User
  • $4,999
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Jul 2016 - Jul 2017)
  • Five Users
  • $6,004
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Jul 2016 - Jul 2017)
  • Enterprise
    License/PDF

  • $9,373
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Jul 2016 - Jul 2017)
  • Library
    Membership

  • $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers